CARBON DIOXIDE, USP (carbon dioxide) by Martin Pharmaceuticals is x-ray contrast activity [moa]. Approved for actinic keratosis. First approved in 2013.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
CARBON DIOXIDE, USP is an inhaled gas product approved as a radiographic contrast agent with X-ray contrast activity mechanism of action. It is indicated for the treatment of actinic keratosis and operates through a unique gas-based delivery system. The product represents an unconventional therapeutic approach to a common dermatologic condition.
Product is at peak lifecycle stage with moderate competitive pressure (30%), indicating stable market position but limited growth runway for commercial expansion.
X-Ray Contrast Activity
Radiographic Contrast Agent
A Study of the Efficacy and Safety of Extracorporeal Carbon Dioxide Removal Using PrismaLung+
Extracorporeal Carbon Dioxide Removal Using PrismaLung in Reducing Ventilator Induced Lung Injury
Carbon Dioxide Investigation
Influence of Caffeine on Psychomotor Vigilance and Carbon Dioxide Tolerance During Graded Hypercapnia
RECELL to Promote Healing Following Carbon Dioxide (CO2) Laser Treatment in Cosmetic Patients
Worked on CARBON DIOXIDE, USP at Martin Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Zero linked jobs indicate limited active hiring for this product, suggesting a stable but mature team structure with minimal expansion planned. Career progression on this product may be constrained by peak lifecycle status and lack of clinical development momentum.